Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia
Targeting Cross-presentation With Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in High Risk Acute Myeloid Leukemia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University Of Michigan Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient must have AML not in remission or at very high risk for HCT (Hematopoietic Cell Transplantation) relapse.
- For newly diagnosed AML, patients must have achieved two consecutive induction attempts without achieving complete remission
- For patients initially in complete remission whose AML relapses > 6 months after preceding remission, one re-induction must be attempted to be eligible
- For AML patients with early relapse, in whom the preceding remission is shorter than 6 months duration, no re-induction regimen is necessary to be eligible
- Patients with antecedent MDS (Myelodysplastic Syndrome) who progress to AML may have therapies rendered during both phases counted towards these requirements.
- Patients with poor cytogenetic or molecular risk associated with very high risk for relapse after HCT may proceed without provisions for prior treatment. However, they must have received at least one induction attempt.
- Patients must be ≥ 18 years of age and considered a candidate for HCT
- Karnofsky ≥ 70% (Karnofsky performance status is measure of a cancer patients general well being and activities of daily life. Scores range from 100 to 0 where 100 is perfect health and 0 is death
- Patients must meet acceptable organ function criteria: Total Bilirubin ≤2.5 mg%; AST (Aspartate transaminase) and ALT (Alanine transaminase) <5.0 X institutional upper limit of normal; GFR (Glomerular filtration rate) >40 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; Lung function tests (DLCO, FEV1, FVC) > 50%; Ejection fraction > 50%
- All patients must sign an informed consent
- Women and men of child-bearing potential must agree to use adequate contraception
Exclusion Criteria:
- Prior chemotherapy treatment for AML within 21 days from the initiation of HCT conditioning
- Patients may NOT have evidence or symptoms of CNS disease at the time of enrollment
- HIV or HTLV1 / HTLV2 (Human T-lymphotrophic virus) (seropositivity and/or PCR positivity)
- Patients less than 18 years of age
- Pregnant and nursing mothers are excluded from this study
- Patients with untreated or uncontrolled neuropsychiatric illness
- Any physical or psychological condition that, in the opinion of the investigator, would pose unacceptable risk to the patient
- Uncontrolled infections
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: peg-IFN-α
peg-IFN-α will be administered prior to HCT (Hematopoietic Cell Transplant) and at three subsequent time points post HCT. (Maximum of 4 doses) It will be administered by subcutaneous injection every 14 days beginning with dose level 1. Dose Level -1 - 45mcg Dose Level 1 - 90mcg Dose Level 2 - 180 mcg |
Other Names:
Calcineurin inhibitor administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.
Cyclosporine may be substituted if patients cannot tolerate tacrolimus.
Administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Phase 1: Maximum Tolerated Dose (MTD) of Peg-IFN-α
Time Frame: Up to day 56 post-transplant or up to 14 days after final treatment with peg-IFN-α, whichever comes later. Data was collected up to 63 days.
|
The dose level assigned to the most participants is selected as the MTD.
Participants from the arms for dose level 1 (90mcg, 3 participants) and dose level 2 (180mcg, 33 participants) were analyzed together to determine the MTD.
Dosage levels are determined by dose-limiting toxicities (DLTs).
Only DLTs encountered during the treatment period, prior to day 56 post HCT (or 14 days after final treatment, whichever comes later), are counted.
DLTs after the treatment period are counted only if they reflect an ongoing toxicity that initiated in the treatment period.
|
Up to day 56 post-transplant or up to 14 days after final treatment with peg-IFN-α, whichever comes later. Data was collected up to 63 days.
|
|
Phase 2: Number of Patients That Relapse
Time Frame: 6 Months Post HCT
|
The cumulative incidence of relapse, estimated using proportional hazard model for the competing risk of non-relapse mortality (NRM).
|
6 Months Post HCT
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Phase 2: Overall Survival Time
Time Frame: 1 year or until study stops, whichever is later. Median time of follow-up was 25 months.
|
Estimated using Kaplan-Meier methods, overall survival (OS) will be calculated from the day of transplantation (day 0) until death; shown at 6 month and 2 year estimates
|
1 year or until study stops, whichever is later. Median time of follow-up was 25 months.
|
|
Phase 2: Event Free Survival Time
Time Frame: 1 year or until study stops, whichever is later. Median time of follow-up was 25 months.
|
Defined for this study as Leukemia Free Survival, and estimated using Kaplan-Meier methods.
|
1 year or until study stops, whichever is later. Median time of follow-up was 25 months.
|
|
Acute GVHD
Time Frame: 6 months
|
Grade 2-4 Acute GVHD estimated using proportional hazards ratio.
Graded according to CTCAE v. 4.0; higher grades represent more severe events.
|
6 months
|
|
Non-Relapse Mortality
Time Frame: 1 year or until study stops, whichever is later. Median time of follow-up was 25 months.
|
The cumulative incidence of non-relapse mortality is estimated by proportional hazard models methods.
|
1 year or until study stops, whichever is later. Median time of follow-up was 25 months.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: John M Magenau, M.D., University of Michigan Rogel Cancer Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Calcineurin Inhibitors
- Methotrexate
- Tacrolimus
Other Study ID Numbers
Other Study ID Numbers
- UMCC 2014.107
- HUM00093471 (Other Identifier: University of Michigan)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.